Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 18/20 | 0.58 |
| ▸ | PPARA | Q07869 | 18/20 | 0.58 |
| ▸ | PPARG | P37231 | 11/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12732408 | 0.94 | PPARA (0.51) | PPARDPPARAPPARGNPC1POLB | |
| SCHEMBL2463893 | 0.92 | PPARD (0.60) | PPARDPPARAPPARGNPC1POLB | |
| SCHEMBL2466219 | 0.92 | PPARA (0.49) | PPARDPPARAPPARGNPC1POLB | |
| SCHEMBL24658521 | 0.89 | PPARA (0.48) | PPARDPPARAPPARGNPC1POLB | |
| SCHEMBL30003956 | 0.89 | PPARA (0.48) | PPARDPPARAPPARGNPC1POLB | |
| SCHEMBL1765900 | 0.87 | PPARD (0.66) | PPARDPPARAPPARGTSHR | |
| SCHEMBL1765978 | 0.87 | PPARA (0.61) | PPARDPPARAPPARGNPC1POLB | |
| SCHEMBL6885086 | 0.87 | PPARA (0.53) | PPARDPPARAPPARGNPC1POLB | |
| SCHEMBL12732409 | 0.85 | PPARG (0.58) | PPARDPPARAPPARGNPC1POLB | |
| SCHEMBL2466184 | 0.85 | PPARD (0.52) | PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652045-B2 | e.g. [[7-Allyl-3-[2-[2-(2,4-dichlorophenyl)-5-isopropyl-4-oxazolyl]ethyl]-1,2-benzisoxazol-6-yl]oxy]acetic acid; with vehicles (lactose, D-mannitol, glucose), disintegrators (starch or carboxymethylcellulose calcium ), binders (hydroxypropylcellulose) and lubricants (magnesium stearate or talc) | NIPPON CHEMIPHAR, CO., LTD. (JP) | 2010-01-26 | — | — | US | claimed |
| EP-2464349-A2 | USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES | Cerenis Therapeutics S.A. (FR) | 2012-06-20 | — | — | EP | disclosed |
| EP-1424330-B1 | ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR DELTA | NIPPON CHEMIPHAR CO (JP) | 2011-09-28 | — | — | EP | disclosed |
| WO-2011020001-A9 | USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES | CERENIS THERAPEUTICS S.A. (FR) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011020001-A9 | USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES | CERENIS THERAPEUTICS S.A. (FR) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011020001-A2 | USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES | CERENIS THERAPEUTICS S.A. (FR) | 2011-02-17 | — | — | WO | disclosed |
| WO-2011020001-A2 | USE OF PPAR DELTA LIGANDS FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR ENERGY METABOLISM/PRODUCTION RELATED DISEASES | CERENIS THERAPEUTICS S.A. (FR) | 2011-02-17 | — | — | WO | disclosed |
| US-7652045-B2 | e.g. [[7-Allyl-3-[2-[2-(2,4-dichlorophenyl)-5-isopropyl-4-oxazolyl]ethyl]-1,2-benzisoxazol-6-yl]oxy]acetic acid; with vehicles (lactose, D-mannitol, glucose), disintegrators (starch or carboxymethylcellulose calcium ), binders (hydroxypropylcellulose) and lubricants (magnesium stearate or talc) | NIPPON CHEMIPHAR, CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-7648999-B2 | Activator for peroxisome proliferator-activated receptor δ | NIPPON CHEMIPHAR CO., LTD. (JP) | 2010-01-19 | — | — | US | disclosed |
| WO-2008154023-A1 | NOVEL USES OF PPAR DELTA AGONISTS | CERENIS THERAPEUTICS S.A. (FR) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008154023-A1 | NOVEL USES OF PPAR DELTA AGONISTS | CERENIS THERAPEUTICS S.A. (FR) | 2008-12-18 | — | — | WO | disclosed |
| US-20080009525-A1 | Activator of peroxisome proliferator-activated receptor delta | SAKUMA SHOGO | 2008-01-10 | — | — | US | disclosed |
| US-20080009631-A1 | Activator for peroxisome proliferator-activated receptor delta | SAKUMA SHOGO | 2008-01-10 | — | — | US | disclosed |
| US-7265137-B2 | Activator of peroxisome proliferator-activated re-ceptor δ | NIPPON CHEMIPHAR CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20050054674-A1 | Activator of peroxisome proliferator-activated receptor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2005-03-10 | — | — | US | disclosed |
| EP-1424330-A1 | ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR DELTA | NIPPON CHEMIPHAR CO., LTD. (JP) | 2004-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009525-A1 | Activator of peroxisome proliferator-activated receptor delta | PPARG, PPARD, PPARA | PPARD 2/4885PPARA 3/4885PPARG 1/4885 |
| US-20080009631-A1 | Activator for peroxisome proliferator-activated receptor delta | PPARG, PPARD, PPARA | PPARD 2/4885PPARA 3/4885PPARG 1/4885 |
| US-20050054674-A1 | Activator of peroxisome proliferator-activated receptor | PPARG, PPARD, PPARA | PPARD 2/4885PPARA 3/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.